Alpha 2.0
Login Register
» Articles » PMID: 24586088

Moving Forward with Expanding to an "all-RAS Mutational Analysis" in Metastatic Colorectal Cancer: Beyond KRAS Mutations

Overview
Journal J Natl Compr Canc Netw
Specialty Oncology
Date 2014 Mar 4
PMID 24586088
Citations 5
Authors
Tanios Bekaii-Saab
Affiliations
Soon will be listed here.
Citing Articles

The Phase II Study of Panitumumab in Chemotherapy-Naïve Frail or Elderly Patients with RAS Wild-type Colorectal Cancer: OGSG 1602 Final Results.

Terazawa T, Kato T, Goto M, Ohta K, Satake H, Noura S Oncologist. 2022; 28(7):e565-e574.

PMID: 35947993 PMC: 10322121. DOI: 10.1093/oncolo/oyac145.

Mutations of KRAS/NRAS/BRAF predict cetuximab resistance in metastatic colorectal cancer patients.

Hsu H, Thiam T, Lu Y, Yeh C, Tsai W, You J Oncotarget. 2016; 7(16):22257-70.

PMID: 26989027 PMC: 5008360. DOI: 10.18632/oncotarget.8076.

Oncologists' Selection of Genetic and Molecular Testing in the Evolving Landscape of Stage II Colorectal Cancer.

Parikh A, Keating N, Liu P, Gray S, Klabunde C, Kahn K J Oncol Pract. 2016; 12(3):e308-19, 259-60.

PMID: 26962170 PMC: 4960467. DOI: 10.1200/JOP.2015.007062.

Extended RAS testing in metastatic colorectal cancer-Refining the predictive molecular biomarkers.

Al-Shamsi H, Alhazzani W, Wolff R J Gastrointest Oncol. 2015; 6(3):314-21.

PMID: 26029459 PMC: 4397245. DOI: 10.3978/j.issn.2078-6891.2015.016.

EPMA position paper in cancer: current overview and future perspectives.

Grech G, Zhan X, Yoo B, Bubnov R, Hagan S, Danesi R EPMA J. 2015; 6(1):9.

PMID: 25908947 PMC: 4407842. DOI: 10.1186/s13167-015-0030-6.